David Kirn - Jul 10, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Executive Officer, Director
Signature: By: /s/ Scott Bizily as Attorney-in-fact David Kirn
Stock symbol: FDMT
Transactions as of: Jul 10, 2024
Transactions value $: -$102,521
Form type: 4
Date filed: 7/12/2024, 05:46 PM
Previous filing: Jun 26, 2024
Next filing: Mar 10, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FDMT	Common Stock	Options Exercise	$168K	+11.7K	+1.1%	$14.42	1.07M	Jul 10, 2024	Direct	F1
transaction	FDMT	Common Stock	Options Exercise	$20K	+1.27K	+0.12%	$15.78	1.07M	Jul 10, 2024	Direct	F1
transaction	FDMT	Common Stock	Sale	-$291K	-12.9K	-1.21%	$22.49	1.06M	Jul 10, 2024	Direct	F1, F2

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right To Buy)	Options Exercise	$0	-11.7K	-2.02%	$0.00	565K	Jul 10, 2024	Common Stock	11.7K	$14.42	Direct	F1, F3
transaction	FDMT	Stock Option (Right To Buy)	Options Exercise	$0	-1.27K	-0.85%	$0.00	149K	Jul 10, 2024	Common Stock	1.27K	$15.78	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.
F2	The transaction was executed in multiple trades in prices ranging from $22.05 to $23.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3	The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F4	The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.